Skip to content

Study · Observational study · n = 75,243 · 2026

2 results

Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.

Tan X, Liang Y, Xie L, Harton J, Gutierrez C, Muhammad C, Swift C, de Havenon A

Diabetes, obesity & metabolism8 Jan 2026Cited by 1 (Europe PMC)

PMID41508706 (opens in a new tab)PMCIDPMC12992163 (opens in a new tab)DOI10.1111/dom.70440 (opens in a new tab)PepBankPUB-41508706
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, the incidence rate of 3-point MACE was 25.7 with semaglutide and 33.0 with dulaglutide.

    In plain wordsIn adults with type 2 diabetes and heart disease, major heart events were less frequent with semaglutide than with dulaglutide.

    Peptide
    Semaglutide
    Outcome
    Decrease3-point MACE incidence rate
    Study

    n = 75,243

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    MACE incidence rate
    25.7 per 1000 person-years
    semaglutide
    MACE incidence rate
    33 per 1000 person-years
    dulaglutide

    Source sentences

    Summary
    The incidence rates of the primary outcome, 3-point MACE, were 25.7 and 33.0 in the semaglutide and dulaglutide cohorts, respectively.
    1 context sentence
    Summary · context
    New initiators of semaglutide or dulaglutide ≥18 years with both T2D and ASCVD were included.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, semaglutide was associated with a 22% lower risk of 3-point MACE than dulaglutide.

    In plain wordsIn adults with type 2 diabetes and heart disease, semaglutide was linked to a lower risk of major heart events than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    Decrease3-point MACE hazard ratio
    Study

    n = 75,243

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    hazard ratio
    0.78 ratio
    3-point MACE, semaglutide vs dulaglutide

    Source sentences

    Summary
    Compared with the dulaglutide cohort, the semaglutide cohort had a 22% lower risk of 3-point MACE (hazard ratio, 0.78 [95% CI, 0.70-0.87]; p < 0.001).
    1 context sentence
    Summary · context
    New initiators of semaglutide or dulaglutide ≥18 years with both T2D and ASCVD were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.